1	Cetus	NNP	2	nn
2	Corp.	NNP	3	nsubj
3	said	VBD	0	root
4	the	DT	5	det
5	government	NN	8	nsubj
6	of	IN	5	prep
7	Spain	NNP	6	pobj
8	approved	VBD	3	ccomp
9	the	DT	10	det
10	marketing	NN	8	dobj
11	of	IN	10	prep
12	its	PRP$	15	poss
13	Proleukin	NNP	15	nn
14	interleukin-2	NN	15	nn
15	drug	NN	11	pobj
16	to	TO	17	aux
17	treat	VB	15	infmod
18	kidney	NN	19	nn
19	cancer	NN	17	dobj
20	.	.	3	punct

1	The	DT	3	det
2	biotechnology	NN	3	nn
3	concern	NN	4	nsubj
4	said	VBD	0	root
5	Spanish	JJ	6	amod
6	authorities	NNS	9	nsubj
7	must	MD	9	aux
8	still	RB	9	advmod
9	clear	VB	4	ccomp
10	the	DT	11	det
11	price	NN	9	dobj
12	for	IN	11	prep
13	the	DT	14	det
14	treatment	NN	12	pobj
15	,	,	9	punct
16	but	CC	9	cc
17	that	IN	19	complm
18	it	PRP	19	nsubj
19	expects	VBZ	9	conj
20	to	TO	21	aux
21	receive	VB	19	xcomp
22	such	JJ	23	amod
23	approval	NN	21	dobj
24	by	IN	21	prep
25	year	NN	26	nn
26	end	NN	24	pobj
27	.	.	4	punct

1	Four	CD	3	num
2	other	JJ	3	amod
3	countries	NNS	7	nsubj
4	in	IN	3	prep
5	Europe	NNP	4	pobj
6	have	VBP	7	aux
7	approved	VBN	0	root
8	Proleukin	NNP	7	dobj
9	in	IN	7	prep
10	recent	JJ	11	amod
11	months	NNS	9	pobj
12	.	.	7	punct

1	Cetus	NNP	4	nsubj
2	is	VBZ	4	aux
3	currently	RB	4	advmod
4	trying	VBG	0	root
5	to	TO	6	aux
6	obtain	VB	4	xcomp
7	federal	JJ	9	amod
8	regulatory	JJ	9	amod
9	clearance	NN	6	dobj
10	for	IN	9	prep
11	U.S.	NNP	12	nn
12	distribution	NN	10	pobj
13	.	.	4	punct


